Navigation Links
Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Date:6/5/2009

SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, is scheduled to provide an overview of the company, including its clinical development and research programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 Sales Horizons, ... of its online sales skills training course ... skills. , MedTech clinical staff spend the majority of ... hospital, standalone medical center, or physician practice – providing ... But why stop there? Sales Horizons believes clinical staff ...
(Date:8/18/2014)... --  Sterne, Kessler, Goldstein & Fox P.L.L.C. , an ... , announced today that it has filed eleven ... the U.S. Patent and Trademark Office (USPTO) on behalf ... (Nasdaq: BRLI).  These IPR petitions aim to nullify eleven ... These patents have been asserted against GeneDx in patent ...
(Date:8/18/2014)... , Aug. 18, 2014 TNI BioTech, Inc. ... pioneering the manufacturing and marketing of innovative therapies for ... Company is providing a second notice of TNI BioTech,s ... making the announcement, Noreen Griffin , founder and ... advance for your participation in the Annual Meeting. On ...
(Date:8/16/2014)... $229,214 grant from the Walmart Foundation to build a ... cut the manufacturing costs of goods, allowing those goods ... formerly built overseas. , The Walmart U.S. Manufacturing Innovation ... in awards to seven research and development institutions at ... through the collaboration between Walmart, the U.S. Conference of ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... know them, from televisions to computers, depend on conducting materials ... pocket sized communications devices and microchips that can fit on ... big demand. Now, Prof. Eran Rabani of Tel Aviv ... Faculty of Exact Sciences, in collaboration with Profs. Uri Banin ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, today announced that the Company,s Board ... John Pappajohn as Chairman of the Board. Mr. Pappajohn ... Dr. Sayare has been a member of PharmAthene,s ...
... Quest Diagnostics (NYSE: DGX ), ... and services, and Genomic Vision, a biotechnology company dedicated ... a multi-year exclusive collaboration involving Genomic Vision,s proprietary ... terms of the agreement, Quest Diagnostics has exclusive ...
Cached Biology Technology:Conducting energy on a nano scale 2Conducting energy on a nano scale 3Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors 2Mitchel Sayare, Ph.D. to Succeed John Pappajohn as Chairman of the Company's Board of Directors 3Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests 2Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests 3Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests 4
(Date:8/19/2014)... August 19, 2014A new ovoid structure discovered in the ... contains a variety of minerals, and shows evidence of ... melting of the permafrost and mixing of surface and ... range of analytical studies to determine the origin of ... how this ovoid formed, point to the most likely ...
(Date:8/19/2014)... that analyzed concentrations of African dust transported to ... and spring. These research findings offer new insight ... impacts of African dust, including the climate change-induced ... from increased African dust emissions in the coming ... Rosenstiel School of Marine and Atmospheric Science and ...
(Date:8/19/2014)... available in French . ... and RISKS of physical activity in children,Today the Canadian ... promotion of childhood physical activity and published their position ... and Metabolism ( APNM ). This position ... area of risk of physical activity for children and ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... variants related to a risk factor for sudden cardiac ... journal Nature Genetics identifies variants in genes, ... QT interval measured on the electrocardiogram (EKG) performed routinely ... prevent sudden cardiac death and arrhythmia by limiting the ...
... Building on these findings, the Helmholtz scientists and their ... pathogenesic mechanisms of the disease and gain perspectives for ... study have been published online in the journal ... international research consortium QTSCD (QT Interval and Sudden Cardiac ...
... 2009 A review by researchers at Northwestern University ... of the utility of probiotics in the treatment of ... 35624 was the only probiotic strain out of ... improve symptoms of IBS, including abdominal pain, bloating and ...
Cached Biology News:Common gene variants influence risk factor for sudden cardiac death 2Common gene variants influence risk factor for sudden cardiac death 3Genetic risk factors identified for sudden cardiac death 2Genetic risk factors identified for sudden cardiac death 3Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms 2
... Staccato Series of systems provide fast ... drug discovery, genomics, proteomics and drug ... in three base configurations; Mini Workstation ... Series. All Staccato Application Series ...
... Workstation fully automates pharmaceutical sample preparation ... sample transfer, mixing and dilutions. Capabilities ... detection. The Prelude performs these functions ... Part 11. The Prelude performs ...
... any standard fixed-angle microcentrifuge rotor at ... centrifuge tube filters consist of a ... tube. They filter by centrifugation for ... preparation, removal of cells from media ...
... seal tabs • Reusable, press-to-seal gasket ... quickly assembled and disassembled for hybridizing and ... any thickness with up to a 13 ... per slide. Minimize specimen handling, eliminate evaporation ...
Biology Products: